Skip to main content
PZ Cormay S.A. logo

PZ Cormay S.A. — Investor Relations & Filings

Ticker · CRM ISIN · PLCMRAY00029 LEI · 2594006HZJ8OSNK56U87 WAR Manufacturing
Open in API
Filings indexed 692 across all filing types
Latest filing 2020-04-24 Management Reports
Country PL Poland
Listing WAR CRM

About PZ Cormay S.A.

https://cormaydiagnostics.com/

PZ Cormay S.A. is a manufacturer and distributor of in-vitro diagnostic (IVD) solutions for medical laboratories and clinics. The company develops, produces, and sells a comprehensive portfolio of diagnostic reagents, laboratory analyzers, and quality control systems. Its offerings cater to key diagnostic areas, including clinical chemistry, hematology, and immunoassay. Key product lines feature the Accent series of chemistry analyzers, the Auryx immunoassay system, and the Mythic family of hematology analyzers. The company integrates its extensive experience in reagent manufacturing with advanced Swiss hematology technology to provide reliable, high-performance, and cost-effective diagnostic tools to a global network of distributors and healthcare professionals.

Recent filings

Filing Released Lang Actions
1._Pismo_Prezesa_Zarzadu_PZ_CORMAY_S.A._2019.pdf
Management Reports Classification · 98% confidence The document is a letter from the Management Board of PZ CORMAY S.A. dated April 24, 2020, presenting the financial results and key information for the year 2019. It discusses consolidated revenues, net loss, impairment charges related to R&D projects (Hermes, BlueBox, Equisse), strategic shifts (focusing on reselling third-party devices), organizational changes, and the impact of COVID-19. This content is characteristic of a Management Discussion and Analysis (MDA) section, which provides management's detailed explanation of financial results, business trends, and outlook, typically accompanying or preceding the full annual financial statements. Since the document explicitly states it is presenting the 'raporty Spółki i Grupy Kapitałowej CORMAY prezentujące wyniki finansowe oraz najważniejsze informacje dotyczące działalności Spółki i Grupy w 2019 r.' (reports of the Company and CORMAY Capital Group presenting financial results and the most important information regarding the activity of the Company and Group in 2019), and it contains narrative analysis rather than just raw figures (which would suggest 10-K or IR), MDA is the most appropriate classification for this management commentary.
2020-04-24 Polish
Zakończenie testów na utratę wartości aktywów - Content (PL)
Regulatory Filings Classification · 90% confidence The document is a regulatory announcement from PZ CORMAY S.A. regarding the results of impairment tests on development assets. It details specific financial impacts (impairment charges and grant revenue recognition) on the 2019 financial statements. While it discusses financial data, it is an announcement of an accounting adjustment rather than a full financial report (10-K or IR) or an audit report. It fits best as a general regulatory filing (RNS) as it provides material information regarding the company's financial position and strategy updates. FY 2019
2020-04-06 Polish
Informacje o potencjalnym wpływie pandemii koronawirusa SARS-CoV-2 na działalność Spółki i Grupy Kapitałowej Spółki - Content (PL)
Management Reports Classification · 99% confidence The document text is a report from PZ CORMAY S.A. written in Polish. It discusses the stable financial situation, the impact of the COVID-19 pandemic on operations (hospital closures, supply chain issues), and potential future impacts (both negative and positive due to sales of immunological reagents for coronavirus testing). This content strongly suggests a management discussion or a report detailing current business conditions and outlook, often associated with interim or annual reporting cycles, but focused on management's perspective on risks and trends. Reviewing the definitions: - 10-K/IR: It is not a full, structured financial report (like a 10-K or IR). - ER: It is not a concise earnings release highlighting key figures. - MDA (Management Reports): This category is defined as 'Management's detailed explanation of financial results, business trends, and outlook.' The text fits this description perfectly as it is a detailed narrative from management about operational stability, identified risks (pandemic), and future outlook. - LTR: While it discusses risks, it is not primarily about legal proceedings. Given the focus on management's assessment of current operations, risks, and outlook in response to a major event (COVID-19), the most appropriate classification is Management Reports (MDA). The document length (2497 chars) is substantial enough to be a standalone report section rather than just a brief announcement (RPA/RNS).
2020-03-25 Polish
Rozpoczęcie testów na utratę wartości aktywów - Content (PL)
Audit Report / Information Classification · 95% confidence The document text, written in Polish, discusses the initiation of impairment testing (testy na utratę wartości) on capitalized development costs as of March 20, 2020, for the purpose of preparing the 2019 annual financial statements. Crucially, the final sentence states: "Informacje o zakończeniu i wynikach przedmiotowych testów Spółka przekaże odrębnym raportem bieżącym" (Information on the completion and results of these tests will be provided by the Company in a separate current report). This indicates the document is an announcement about an ongoing process or a preliminary step, not the final result or the full financial report itself. Since the content relates to accounting principles (MSR 36) and financial statement preparation but is not the final Audit Report (AR) or the full Annual Report (10-K), and it explicitly defers the results to a future report, it best fits the category for general regulatory/financial updates that don't fit elsewhere, or potentially a preliminary disclosure related to accounting judgments. Given the specific nature of discussing impairment testing for financial statements, it is closely related to the Audit Report/Information category (AR), but since it is only announcing the *start* of the test and promising results later, it functions as a regulatory update. However, if the final results were included, it would be AR. Since this is a preliminary disclosure about an accounting procedure impacting the financials, and it's not a standard ER or IR, the closest fit among the specific options related to financial review/audit is AR, although it is a precursor. Given the context of financial statement preparation and accounting tests, AR is the most relevant category for the *subject matter*, even if this specific filing is just an announcement. If the document was purely announcing the *publication* of a report, RPA would be chosen, but this announces the *start of a process* impacting the financials. I will classify this as AR based on the subject matter (impairment testing for annual statements), recognizing it's a preliminary notice. FY 2019
2020-03-20 Polish
P._Markowska_PZ_CORMAY_S.A._06.03.2020.pdf
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). This regulation (MAR - Market Abuse Regulation) mandates disclosures for transactions conducted by persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. The content details a 'Zbycie' (Sale) of 'AKCJA' (Shares) by an individual closely associated with a member of the Supervisory Board ('Członek Rady Nadzorczej'). This directly corresponds to the definition of Director's Dealing (insider trades). Comparing this to the provided definitions: - 10-K, AR, IR are comprehensive financial reports. - ER is an earnings release. - DIV is a dividend notice. - The document explicitly reports personal share transactions by an insider/related party. This matches the definition for Director's Dealing (Code: DIRS).
2020-03-09 Polish
T._Markowski_PZ_CORMAY_S.A._06.03.2020.pdf
Director's Dealing Classification · 99% confidence The document is titled "Powiadomienie o transakcji/tramsakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). This regulation (MAR - Market Abuse Regulation) governs insider dealing and market manipulation. Section 1 identifies the person as a manager/insider (Tomasz Markowski, Członek Rady Nadzorczej - Supervisory Board Member). Section 4 details the transaction: 'Rodzaj transakcji' (Type of transaction) is 'Zbycie' (Sale/Disposal) of shares ('AKCJA'). This clearly indicates a report of personal share transactions by a company director or executive, which aligns perfectly with the definition of Director's Dealing (DIRS). The document length is short (4883 chars), but it is the primary report itself, not an announcement of a report, so RPA/RNS is not the primary classification.
2020-03-09 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.